Correction: Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src [Oncotarget, 7, 22, (33111-33124) (2016)] DOI: 10.18632/oncotarget.8880

0Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

Present: Due to an error in proofreading, a research project number was accidentally omitted from the Acknowledgments list. Correct: The correct numbers are provided below. The authors sincerely apologize for this oversight. Original article: Oncotarget. 2016; 7(22):33111-24. doi: 10.18632/oncotarget.8880.

Cite

CITATION STYLE

APA

Perez, M., Lucena-Cacace, A., Marín-Gómez, L. M., Padillo-Ruiz, J., Robles-Frias, M. J., Saez, C., … Carnero, A. (2016). Correction: Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src [Oncotarget, 7, 22, (33111-33124) (2016)] DOI: 10.18632/oncotarget.8880. Oncotarget. Impact Journals LLC. https://doi.org/10.18632/oncotarget.13482

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free